Novacyt (NCYT) EUR0.0667 (CDI)
- Add to watchlist
- Create an alert
- This stock can be held in a
72.00p
74.00p
85.40p
£49.44 million
71.40p
67.21p
36.15p
n/a
3.40p (5.00%) Previous:
3.40p
88,967
n/a
7,500
Performance
Not available for this stock.
Fundamental data
Year ending: | 31/12/2022 | 31/12/2021 |
---|---|---|
Revenue (£m) | 21.04 | 92.60 |
Profit before tax (£m) | (20.05) | (5.66) |
Adjusted EPS (p): | (31.00) | (9.00) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Novacyt gearing up for hearing in DHSC litigation
19 April 2024 11:02
-
Novacyt confirms end of Yourgene Taiwan disposal discussions
6 February 2024 12:48
-
Novacyt taps Steve Gibson for CFO
2 January 2024 08:12
-
Long Term Incentive Plan
23 April 2024 07:00
-
DHSC Claim update – Pre-Trial Review
19 April 2024 07:00
-
Directorate Changes and FY 23 results update
11 April 2024 07:00
Recent trade data is unavailable. We will be replacing it, however in the meantime the information is available on the London Stock Exchange website.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.